

Form PTO-1449 (modified)		Temp. Atty. Docket No. 4001.002299	Serial No. 09/998,833
List of Patents and Publications for Applicant's  INFORMATION DISCLOSURE STATEMENT  (Use several sheets if necessary)		Applicant Thorpe <i>et al.</i>	
		Filing Date: November 30, 2001	Group: 1642
U.S. Patent Documents <i>See Page 1</i>	Foreign Patent Documents <i>See Page</i>	Other Art <i>See Pages 1-4</i>	

### U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.
BF	A40	2003/0228625	Dec. 11, 2003	Toh <i>et al.</i>	435	7.1	
BF	A41	5,677,171	Oct. 14, 1997	Hudziak <i>et al.</i>	435	7.23	
BF	A42	6,333,348	Dec. 25, 2001	Vogel <i>et al.</i>	514	449	
BF	A43	7,067,109	Jun. 27, 2006	Thorpe <i>et al.</i>	424	1.49	

### Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Class	Sub Class	Translation Yes/No

### Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
BF	C121	Andre <i>et al.</i> , "Angiogenese Tumorale: Physiopathologic, Valeur Pronostique et Perspectives Therapeutiques", <i>Rev. Med. Interne.</i> , 19:904-913, 1998.
	C122	Balasubramanian and Schroit, "Aminophospholipid Asymmetry: A Matter of Life and Death", <i>Annu. Rev. Physiol.</i> , 65:701-734, 2003.
	C123	Beck <i>et al.</i> , "Combination of a Monoclonal Anti-Phosphatidylserine Antibody with Gemcitabine Strongly Inhibits the Growth and Metastasis of Orthotopic Pancreatic Tumors in Mice," <i>Int. J. Cancer</i> , 118:2639-2643, 2006.
BF	C124	Bowie <i>et al.</i> , "Deciphering the Message in Protein Sequences: Tolerance to Amino Acid Substitutions", <i>Science</i> , 147:1306-1310, 1990.

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)	Temp. Atty. Docket No. 4001.002299	Serial No. 09/998,833
List of Patents and Publications for Applicant's  INFORMATION DISCLOSURE STATEMENT  (Use several sheets if necessary)	Applicant Thorpe <i>et al.</i>	
	Filing Date: November 30, 2001	Group: 1642
U.S. Patent Documents <i>See Page 1</i>	Foreign Patent Documents <i>See Page</i>	Other Art <i>See Pages 1-4</i>

### Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
BF	C125	Burgess <i>et al.</i> , "Possible Dissociation of the Heparin-binding and Mitogenic Activities for Heparin-binding (Acidic Fibroblast) Growth Factor-1 from Its Receptor-binding Activities by Site-directed Mutagenesis of a Single Lysine Residue", <i>J. Cell Biol.</i> , 111:2129-2138, 1990.
	C126	Chatterjee <i>et al.</i> , "Idiotypic Antibody Immunotherapy of Cancer", <i>Cancer Immunol. Immunother.</i> , 38:75-82, 1994.
	C127	Curti, "Physical Barriers to Drug Delivery in Tumors", <i>Critical Reviews in Oncology/Hematology</i> , 14:29-39, 1993.
	C128	Gura, "Systems for Identifying New Drugs Are Often Faulty", <i>Science</i> , 273:1041-1042, 1997.
	C129	Güssow and Seemann, "Humanization of Monoclonal Antibodies", <i>Methods in Enzymology</i> , 203:99-121, 1991.
	C130	He & Thorpe, "Anti-tumor Effects of Duramycin-IgG Conjugate Targeted to Phosphatidylethanolamine on Tumor Blood Vessels", Presentation #4561, 95th AACR Annual Meeting, March 27-31, 2004, Orlando, Florida.
	C131	Huang <i>et al.</i> , "A Monoclonal Antibody that Binds Anionic Phospholipids on Tumor Blood Vessels Enhances the Antitumor Effect of Docetaxel on Human Breast Tumors in Mice", <i>Cancer Res.</i> , 65(10):4408-4416, 2005.
	C132	Ibragimova and Wade, "Stability of the $\beta$ -Sheet of the WW Domain; A Molecular Dynamics Simulation Study", <i>Biophysical Journal</i> , 77:2191-2198, 1999.
	C133	Janeway <i>et al.</i> , Immunobiology: The Immune System in Health and Disease", <i>Immunobiology</i> , 5th ed., 2001.
↓	C134	Lazar <i>et al.</i> , "Transforming Growth Factor $\alpha$ : Mutation of Aspartic Acid 47 and Leucine 48 Results in Different Biological Activities", <i>Mol. Cell. Biol.</i> , 8(3):1247-1252, 1988.
BF	C135	Lewis <i>et al.</i> , "Differential Responses of Human Tumor Cell Lines to Anti-p185 <sup>HER2</sup> Monoclonal Antibodies", <i>Cancer Immunol. Immunother.</i> , 37:255-263, 1993.

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)		Temp. Atty. Docket No. 4001.002299	Serial No. 09/998,833
List of Patents and Publications for Applicant's  INFORMATION DISCLOSURE STATEMENT  (Use several sheets if necessary)		Applicant Thorpe <i>et al.</i>	
		Filing Date: November 30, 2001	Group: 1642
U.S. Patent Documents <i>See Page 1</i>	Foreign Patent Documents <i>See Page</i>	Other Art <i>See Pages 1-4</i>	

### Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
BF	C136	Lin <i>et al.</i> , "Structure-Function Relationships in Glucagon: Properties of Highly Purified Des-His <sup>1</sup> , Monoiodo-, and [Des-Asn <sup>28</sup> , Thr <sup>29</sup> ](homoserine lactone <sup>27</sup> )-glucagon, <i>Biochemistry</i> , 14(8):1559-1563, 1975.
	C137	Luster <i>et al.</i> , "Plasma Protein Beta-2-Glycoprotein 1 Mediates Interaction Between the Anti-tumor Monoclonal Antibody 3G4 and Anionic Phospholipids on Endothelial Cells", <i>J. Biol. Chem.</i> , 281(40):29863-29871, 2006.
	C138	Marconescu <i>et al.</i> , "Coincident Exposure of Phosphatidylethanolamine and Phosphatidylserine on the Surface of Irradiated Endothelial Cells", Presentation #1053, 97th AACR Annual Meeting, Washington, DC, April 1-5, 2006.
	C139	Mellman, "Where Next for Cancer Immunotherapy?", <i>The Scientist</i> , 20(1):47-56, 2006.
	C140	Molema <i>et al.</i> , "The Use of Bispecific Antibodies in Tumor Cell and Tumor Vasculature Directed Immunotherapy", <i>Journal of Controlled Release</i> , 64:229-239, 2000.
	C141	Ran and Thorpe, "Phosphatidylserine is a Marker of Tumor Vasculature and a Potential Target for Cancer Imaging and Therapy", <i>Int. J. Radiation Oncology Biol. Phys.</i> , 54(5):1479-1484, 2002.
	C142	Ran <i>et al.</i> , "Antitumor Effects of a Monoclonal Antibody that Binds Anionic Phospholipids on the Surface of Tumor Blood Vessels in Mice", <i>Clin. Cancer Res.</i> , 11:1551-1562, 2005.
	C143	Rauch <i>et al.</i> , "Human Hybridoma Lupus Anticoagulants Distinguish between Lamellar and Hexagonal Phase Lipid Systems", <i>J. Biol. Chem.</i> , 261(21):9672-9677, 1986.
	C144	Rudikoff, "Single Amino Acid Substitution Altering Antigen-Binding Specificity", <i>Proc. Natl. Acad. Sci. USA</i> , 79:1979-1983, 1982.
↓	C145	Schneider-Gadicke <i>et al.</i> , "Prevention of Manifest Metastasis with Monoclonal Antibodies: A Novel Approach to Immunotherapy of Solid Tumours", <i>Eur. J. Cancer</i> , 31A(7/8):1326-1330, 1995.
BF	C146	Schwartz <i>et al.</i> , "A Superactive Insulin: [B10-Aspartic acid]Insulin(Human)", <i>Proc. Natl. Acad. Sci. USA</i> , 84:6408-6411, 1987.

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)		Temp. Atty. Docket No. 4001.002299	Serial No. 09/998,833
List of Patents and Publications for Applicant's  INFORMATION DISCLOSURE STATEMENT  (Use several sheets if necessary)		Applicant Thorpe <i>et al.</i>	
		Filing Date: November 30, 2001	Group: 1642
U.S. Patent Documents <i>See Page 1</i>	Foreign Patent Documents <i>See Page</i>	Other Art <i>See Pages 1-4</i>	

### Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
BF	C147	Seaver, "Monoclonal Antibodies in Industry: More Difficult Than Originally Thought", <i>Genetic Engineering News</i> , 20-21, 1994.
	C148	Songsivilai <i>et al.</i> , "A Novel Strategy for Producing Chimeric Bispecific Antibodies by Gene Transfection", <i>Biochem. Biophys. Res. Comm.</i> , 164(1):271-276, 1989.
	C149	Songsivilai & Lachmann, "Bispecific Antibody: A Tool for Diagnosis and Treatment of Disease", <i>Clin. Exp. Immunol.</i> , 79:315-321, 1990.
	C150	Stancovski <i>et al.</i> , "Mechanistic Aspects of the Opposing Effects of Monoclonal Antibodies to the ERBB2 Receptor on Tumor Growth", <i>Proc. Natl. Acad. Sci. USA</i> , 88:8691-8695, 1991.
	C151	Strobel and Cannistra, " $\beta$ 1-Integrins Partly Mediate Binding of Ovarian Cancer Cells to Peritoneal Mesothelium in Vitro", <i>Gynecologic Oncology</i> , 73:362-367, 1999.
	C152	Thiagarajan and Benedict, "Inhibition of Arterial Thrombosis by Recombinant Annexin V in a Rabbit Carotid Artery Injury Model", <i>Circulation</i> , 96(7):2339-2347, 1997.
	C153	Wessels, "Current Status of Animal Radioimmunotherapy", <i>Cancer Res. (Suppl.)</i> , 50:970-973, 1990.
BF	C154	Wright <i>et al.</i> , "Genetically Engineered Antibodies: Progress and Prospects", <i>Crit. Rev. in Immunol.</i> , 12(3,4):125-168, 1992.

EXAMINER: /Brandon Fetterolf/

DATE CONSIDERED: 3/24/2008

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.